


Use of the Curtius Rearrangement of Acryloyl Azides in the Synthesis of 3,5-Disubstituted Pyridines: Mechanistic Studies

Ta-Hsien Chuang,^{*,†} Yu-Chi Chen,[‡] and Someshwar Pola[§]

[†]School of Pharmacy, China Medical University, Taichung, 40402, Taiwan, Republic of China, [‡]Department of Cosmetic Science, Vanung University, Chung-Li, Tao-Yuan 32045, Taiwan, Republic of China, and [§]Department of Chemistry, Kakatiya University, Warangal, India

thchuang@mail.cmu.edu.tw

Received July 15, 2010



A series of disubstituted pyridine derivatives was synthesized from the corresponding acryloyl azides by acetic acid-promoted cycloaddition. This represents a novel and convenient synthetic approach to the symmetric 3,5-disubstituted pyridines. The nature of the substituent on the double bond and the utilized solvent were found to be crucial to the yield of pyridines. The reactivity of the acid-promoted cycloaddition increases with the presence of aryl groups, such as phenyl and pyridinyl. We also explored the comprehensive mechanism by the acid-promoted cycloaddition of ¹³C-labeled cinnamoyl azide. The symmetric 3,5-disubstituted pyridines were synthesized from acryloyl azides by acetic acid-promoted trimolecular condensation.

Introduction

Many natural products and synthetic compounds containing the pyridine ring system display various pharmacological activities.¹ The methodologies for the synthesis of pyridine derivatives are an important research area in both medicinal and synthetic chemistry.² Among pyridine derivatives, Sch-21418, a 3,5-bis(4-hydroxyphenyl)pyridine, showed good inhibitory activity against inflammatory factors (e.g., interleukin-6),³ and the bis-imidiazolyl pyridine **1** also demonstrated moderate anti-HIV-1 activity as well as toxicity against *Pneumocystis carinii* in the immunosuppressed rat model.⁴ In addition, dipyridinyl compound **2** was reported to represent a suitable substance with an inhibitory effect on the cortex of the adrenal gland.⁵ Some of the 3,5-disubstituted

pyridines displayed significant antimicrobial activity.⁶ The extensive range of pharmacological properties that 3,5-disubstituted pyridines displayed had drawn the attention of chemists. Different methods have been utilized to access 3,5-disubstituted pyridines. These are Chichibabin-type condensation,⁷ cross-Mannich reaction,⁸ cycloadditions of azadienes with enamines,⁹ and the palladium-catalyzed Suzuki–Miyaura coupling reaction from 3,5-dihalopyridines.¹⁰ In this paper, we report an inexpensive and air/moisture-insensitive

(1) (a) Balasubramanian, M.; Keay, J. G. In *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R., Rees, C. W., Scriven, E. F. V., Eds.; Pergamon: Oxford, 1996; Vol. 5, pp 245–300. (b) Spitzner, D. In *Science of Synthesis*; Black, D. St. C., Ed.; Thieme: Stuttgart, 2004; pp 11–284.

(2) (a) Fraser, H. L.; Hopper, D. W.; Kutterer, K. M. K.; Crombie, A. L. In *Progress In Heterocyclic Chemistry*; Gribble, G. W., Joule, J. A., Eds.; Elsevier: Amsterdam, 2008; Vol. 19, pp 314–352. (b) Hopper, D. W.; Kutterer, K. M. K.; Crombie, A. L.; J. J. Clemens. In *Progress In Heterocyclic Chemistry*; Gribble, G. W., Joule, J. A., Eds.; Elsevier: Amsterdam, 2009; Vol. 20, pp 289–332.

(3) Tagat, J. R.; McCombie, S. W.; Barton, B. E.; Jackson, J.; Shortall, J. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 2143–2146.

(4) Kumar, A.; Rhodes, R. A.; Spychala, J.; Wilson, W. D.; Boykin, D. W.; Tidwell, R. R.; Dykstra, C. C.; Hall, J. E.; Jones, S. K.; Schinazi, R. F. *Eur. J. Med. Chem.* **1995**, *30*, 99–106.

(5) Durinda, J.; Szűcs, L.; Struhavova, L.; Kolencs, J.; Heger, J. *Cesk. Farm.* **1972**, *21*, 276–282.

(6) Attia, A.; Abo-Ghalia, M. H.; El-Salam, O. I. *Abd. Pharmazie* **1995**, *50*, 455–459.


(7) (a) Eliel, E. L.; McBride, R. T.; Kaufmann, S. *J. Am. Chem. Soc.* **1953**, *75*, 4291–4296. (b) Panzella, L.; Donato, P. D.; Comes, S.; Napolitano, A.; Palumbo, A.; d'Ischia, M. *Tetrahedron Lett.* **2005**, *46*, 6457–6460. (c) Burns, N. Z.; Baran, P. S. *Angew. Chem., Int. Ed.* **2008**, *47*, 205–208.

(8) Winter, A.; Risch, N. *Synthesis* **2003**, 2667–2670.


(9) (a) Komatsu, M.; Ohgishi, H.; Takamatsu, S.; Ohshiro, Y.; Agawa, T. *Angew. Chem., Int. Ed. Engl.* **1982**, *21*, 213–214. (b) Ohta, K.; Iwaoka, J.; Kamijo, Y.; Okada, M.; Nomura, Y. *Nippon Kagaku Kaishi* **1989**, 1593–1600. (c) Vijn, R. J.; Arts, H. J.; Green, R.; Castelijns, A. M. *Synthesis* **1994**, 573–578. (d) Balasubrahmanyam, S. N.; Jeyashri, B.; Namboothiri, I. N. N. *Tetrahedron* **1994**, *50*, 8127–8142.

(10) (a) Couve-Bonnaire, S.; Carpentier, J. -F.; Mortreux, A.; Castanet, Y. *Tetrahedron* **2003**, *59*, 2793–2799. (b) Liu, Y.; Khemtong, C.; Hu, J. *Chem. Commun.* **2004**, 398–399. (c) Berthiol, F.; Kondolff, I.; Doucet, H.; Santelli, M. *J. Organomet. Chem.* **2004**, *689*, 2786–2798. (d) Khanapure, S. P.; Garvey, D. S. *Tetrahedron Lett.* **2004**, *45*, 5283–5286. (e) Jacquemard, U.; Routier, S.; Dias, N.; Lansiaux, A.; Goossens, J.-F.; Bailly, C.; Mérour, J.-Y. *Eur. J. Med. Chem.* **2005**, *40*, 1087–1095. (f) Kuhnert, N.; Patel, C.; Jami, F. *Tetrahedron Lett.* **2005**, *46*, 7575–7579. (g) Li, J. H.; Zhang, Y. H.; Song, R. J.; Xie, Y. X.; Deng, C. L.; Liang, Y. *Synthesis* **2007**, 2957–2966. (h) Gallon, B. J.; Kojima, R. W.; Kaner, R. B.; Diaconescu, P. L. *Angew. Chem., Int. Ed.* **2007**, *46*, 7251–7254.


SCHEME 1. Synthesis of Isoquinolinones




SCHEME 2. Acid-Promoted Cycloaddition of Acryloyl Azides 4



- a: R = phenyl
 b: R = 4-methoxyphenyl
 c: R = 3-methoxyphenyl
 d: R = 2-methoxyphenyl
 e: R = 4-nitrophenyl
 f: R = 3-nitrophenyl
 g: R = 2-nitrophenyl
 h: R = 3-pyridyl
 i: R = ethoxycarbonyl
 j: R = *n*-propyl
 k: R = *n*-butoxy



synthetic approach to the symmetrical 3,5-disubstituted pyridines by thermal cycloaddition of acryloyl azides in acid solution. We also discuss the detailed mechanism, using ^{13}C -labeled cinnamoyl azide. This is the first time acid-promoted thermal cycloaddition of acryloyl azide has been studied.




- X = OH, **Sch-21418**
 X = 4,5-dihydro-1*H*-imidazol-2-yl, **1**
 X = β -(3-pyridyl)acryloyl, **2**

Results and Discussion

Previously, we reported that cinnamoyl azides in refluxing *o*-dichlorobenzene could undergo Curtius rearrangement to form the corresponding isocyanates and subsequent $\text{Hg}(\text{OAc})_2$ -catalyzed cyclization afforded isoquinolinones (Scheme 1).¹¹

Intriguingly, refluxing a solution of (*E*)-cinnamoyl azide **4a** in acetic acid for 4 h gave rise to two pyridine derivatives. The products were identified as 3,5-diphenylpyridine **5a** and 2-benzyl-3,5-diphenylpyridine **6a**. These were obtained in a yield of 36% and 8%, respectively, by comparing their physical data with those from the literature.¹² No isoquinolinone was obtained (Scheme 2). The complete assignments of the ^1H and ^{13}C NMR signals of these two pyridines (**5a** and **6a**) were easily obtained from the 2D-NMR spectra, using techniques such as COSY, HMQC, HMBC, and NOESY. In the case of **5a**, protons of the phenyl groups were assigned by the COSY correlations. The remaining two mutually coupled aromatic signals at δ 8.05 (1H, t, $J = 2.2$ Hz) and 8.83 (2H, d, $J = 2.2$ Hz) were assigned to H-4 and the

SCHEME 3. Insight into the Fate of a ^{13}C -Labeled Cinnamoyl Azide, **4a- ^{13}C** 

two protons at H-2 and H-6, respectively. They showed a HMQC correlation with the quaternary carbons C-1' (δ 137.8) of phenyl rings and NOE correlation with the ortho protons H-2' (δ 7.65) of the phenyl rings, suggesting that **5a** was 3,5-diphenylpyridine. However, for **6a**, the ^1H NMR signals between δ 7.05 and 7.61 ($J = 2.0$ Hz) meta-coupled with each other and were assigned to H-4 and H-6, respectively. The aliphatic region of the ^1H NMR spectrum of **6a** presented a two-proton singlet at δ 4.19 attributed to benzylic protons. From the HMQC correlations, the assignments of hydrogen-carbon bonds were easily achieved. Further, the key HMQC correlations of CH_2 with C-2''' (δ 128.8) and C-3 (δ 137.3); H-4 with C-1' (δ 139.6) and C-1'' (δ 137.5); and H-6 with C-1'' and the NOE correlations of CH_2 with H-2'' and H-2'''; H-4 with H-2'' and H-2'''; and H-6 with H-2'' confirmed compound **6a** had the structure of 2-benzyl-3,5-diphenylpyridine. Based on the presence of three phenyl rings in **6a**, our preliminary assumption was that the reaction involved a trimolecular condensation mechanism.

To unequivocally establish that the cycloaddition was a trimolecular condensation reaction, a labeled [2- ^{13}C]-cinnamoyl azide, **4a- ^{13}C** , was synthesized using Knoevenagel condensation between benzaldehyde and [2- ^{13}C]malonic acid to form (*E*)-[2- ^{13}C]cinnamic acid, **3a- ^{13}C** .¹³ Chlorination and azide formation,¹¹ followed by subsequent treatment of a solution of the azide **4a- ^{13}C** in HOAc at reflux, produced two labeled pyridines, **5a- ^{13}C** and **6a- ^{13}C** (Scheme 3). The distribution of ^{13}C in the resulting products was examined. Symmetric **5a- ^{13}C** presented ^1H NMR signals similar to those of **5a** except the signals H-2 [δ 8.82 (2H, dddd, $J = 165.4, 10.2, 5.5, 2.2$ Hz)] and H-4 [δ 8.05 (1H, dtt, $J = 159.3, 5.6, 2.2$ Hz)] showed 4J ^1H - ^1H coupling (2.2 Hz) as well as 1J and 3J coupling between ^1H and labeled ^{13}C . In addition, the ^{13}C NMR spectrum displayed two intense peaks for the labeled C-2, C-6 (δ 147.0) and C-4 (δ 132.9). Thus, **5a- ^{13}C** had the structure 3,5-diphenyl-[2,4,6- $^{13}\text{C}_3$]pyridine. Similarly, compound **6a- ^{13}C** also showed two complicated ^1H signals for H-4 [δ 7.74 (1H, dtd, $J = 159.7, 6.1, 2.4$ Hz)] and H-6 [δ 8.83 (1H, dddd, $J = 177.6, 11.2, 5.5, 2.4$ Hz)] and three intense ^{13}C peaks for C-2 (δ 156.6), C-4 (δ 136.1), and C-6 (δ 146.7), indicating the structure 2-benzyl-3,5-diphenyl-[2,4,6- $^{13}\text{C}_3$]pyridine. Therefore, from the pattern of incorporation of three ^{13}C units into each product, we drew the conclusion that

(11) Chuang, T. H.; Wu, P. L. *J. Chin. Chem. Soc.* **2006**, *53*, 413–420.

(12) (a) Farley, C. P.; Eliel, E. L. *J. Am. Chem. Soc.* **1956**, *78*, 3477–3481.
 (b) Jeyashri, B.; Balasubrahmanyam, S. N. *Indian J. Chem., Sect. B* **1985**, *24*, 341–349.

(13) Hano, Y.; Shimazaki, M.; Nomura, T.; Ueda, S. *Heterocycles* **1999**, *50*, 989–994.

TABLE 1. Formation of Pyridines **5a** and **6a** from Cinnamoyl Azide **4a**

| entry | solvent | HOAc (equiv) | temp (°C) | time (h) | product (%) | |
|-------|-----------------------------------|--------------|------------------|----------|-------------|-----------|
| | | | | | 5a | 6a |
| 1 | CH ₃ CO ₂ H | | reflux | 4 | 36 | 8 |
| 2 | <i>o</i> -dichlorobenzene | 10 | 150 | 4 | | 5 |
| 3 | <i>o</i> -dichlorobenzene | 1.2 | 150 | 4 | | 1 |
| 4 | toluene | 10 | 150 ^a | 4 | 15 | 6 |
| 5 | toluene | 1.2 | 150 ^a | 4 | 8 | 2 |
| 6 | DMF | 10 | 150 | 4 | 50 | 2 |
| 7 | DMF | 5 | 150 | 4 | 26 | 13 |
| 8 | DMF | 1.2 | 150 | 4 | 21 | |
| 9 | DMSO | 10 | 150 | 4 | 62 | 12 |
| 10 | DMSO | 5 | 150 | 4 | 45 | 8 |
| 11 | DMSO | 1.2 | 150 | 4 | 40 | 6 |
| 12 | DMSO | 10 | 100 | 4 | 28 | 21 |
| 13 | DMSO | 10 | 150 | 24 | 61 | 4 |
| 14 | DMSO ^b | 10 | 150 | 4 | 25 | 31 |

^aSealed tube was used. ^b0.5 mL of H₂O was added.

TABLE 2. Thermal Cycloaddition of Acryloyl Azide **4** to Give Pyridine Derivatives **5** and **6**^a

| entry | 4 , R = | product (%) | |
|-------|-----------------------------|----------------|----------------------------|
| 1 | 4a , phenyl | 5a (62) | 6a (12) |
| 2 | 4b , 4-methoxyphenyl | 5b (47) | 6b (6) |
| 3 | 4c , 3-methoxyphenyl | 5c (58) | 6c (7) |
| 4 | 4d , 2-methoxyphenyl | 5d (51) | 6d (10) |
| 5 | 4e , 4-nitrophenyl | 5e (48) | |
| 6 | 4f , 3-nitrophenyl | 5f (66) | |
| 7 | 4g , 2-nitrophenyl | 5g (58) | |
| 8 | 4h , pyridin-3-yl | 5h (70) | |
| 9 | 4i , ethoxycarbonyl | 5i (33) | |
| 10 | 4j , propyl | 5j (2) | 6j (21) |
| 11 | 4k , butoxy | | 7 (10) ^b |


^aReaction conditions: acryloyl azides **4** and 10 equiv of HOAc in DMSO at 150 °C for 4 h. ^b2-Butoxymethyl-5-butoxypyridine **7** was obtained, as in eq 1.

formation of pyridines **5a** and **6a** involved a trimolecular condensation of cinnamoyl azide.

The effects of the reaction conditions on the reaction of **4a** are summarized in Table 1. First, a mixture of the azide **4a** and 1.2 equiv of HOAc in *o*-dichlorobenzene or toluene was heated at 150 °C, and only a few pyridine derivatives were obtained. Even when 10 equiv of HOAc was added, the yield of cycloaddition was not enhanced (entries 2–5). When polar solvents such as DMF and DMSO were used, the pyridine derivatives **5a** and **6a** were obtained in higher yields (entries 6–11). Therefore, the efficiency of cycloaddition depends on the solvent polarity and the amount of acetic acid added. Second, the pyridine derivatives remained intact even after an extended period of 24 h at high temperature (entry 13). In addition, the cycloaddition could proceed under milder temperature conditions (100 °C, entry 12), but was less efficient. Third, when wet DMSO was used as the solvent, the yield of 3,5-diphenylpyridine **5a** decreased and the yield of trisubstituted pyridine **6a** increased (compare entry 14 with entry 9). On the basis of the results above, all of the acid-promoted cycloadditions reported in Table 2 were conducted under the optimum conditions described in entry 9: a solution of the acryloyl azide and 10 equiv of HOAc in DMSO was heated at 150 °C under nitrogen for 4 h.

A series of acryloyl azides **4a–k** was obtained from the reactions of acrylic acids **3a–k** with oxalyl chloride followed by the addition of sodium azide.¹¹ The azide product yields were high. The results of one-pot reactions of a DMSO

solution containing an acryloyl azide and 10 equiv of HOAc at 150 °C (or 100 °C for entry 12) for 4 h forming the corresponding pyridine derivatives **5** and **6** are shown in Table 2. The acryloyl azides **4b–d** with the methoxyphenyl group, an electron-donating substituent on the aromatic ring, produced the disubstituted pyridines **5b–d** in moderate yields and trisubstituted pyridines **6b–d** in minimum yields, as shown in entries 2–4. In cases of the acryloyl azides **4e–g** bearing an electron-deficient aromatic ring, such as the nitrophenyl group, the disubstituted pyridines **5e–g** were obtained in good to moderate yields and the production of **6** was inhibited (entries 5–7). The pyridinyl azide **4h** gave the best yield of **5h** (entry 8). However, when 3-(ethoxycarbonyl)-acryloyl azide **4i** and 2-hexenoyl azide **4j** were utilized, instead of the arylacryloyl azides, the cycloadditions were retarded based on the yields of disubstituted pyridines **5i** (33%) and **5j** (2%) as well as the trisubstituted pyridine **6j** (21%), respectively (entries 9 and 10). To our surprise, when the acryloyl azide **4k**, possessing the strong electron-donating group –OBu, directly attached to the terminal double bond, was subjected to the acidic conditions, it was almost impossible to isolate the anticipated pyridines **5k** and **6k**. Only 2-butoxymethyl-5-butoxypyridine **7** was obtained in 10% yield along several complicated irresolvable products (entry 11 and eq 1). Clearly, the reactivity of the acid-promoted cycloadditions of acryloyl azides was increased by the presence of the aryl groups on the double bond.



Mechanistic Study

By carefully examining the crude products obtained from the cycloaddition using cinnamoyl azide **4a** as the starting material, acetamide (68%), and a trace amount of toluene, 4-benzyl-5-phenyl-3,4-dihydro-1*H*-pyrimidin-2-one **8a** and 3,5-diphenylpyridin-2-one **9a** could be isolated along with **5a** (62%) and **6a** (12%). The structures of both **8a** and **9a** were proven by COSY, HMQC, HMBC, and NOESY experiments. Similarly, if 3-nitrocinnamoyl azide **4f** was used, diarylpyridine **5f** (66%), acetamide (60%), and 3-nitrotoluene (5%) were isolated. On the basis of the above results, a complete mechanistic route for the formation of pyridines **5**, **6**, and **7**, pyrimidinone **8**, and pyridinone **9** through an acid-promoted cycloaddition of azides **4** as depicted in Scheme 4 is proposed.


First, the reactant, **4**, underwent Curtius rearrangement to form the isocyanate **10**. Once **10** was formed, the electron-deficient isocyanate facilitated nucleophilic attack by HOAc to give adduct **11**,¹⁴ resulting in a reversible dissociation–recombination process between **10** and **11**. The enamide **11** was supposed to equilibrate with unstable mixed anhydride **12** at high temperature.¹⁵ The preferential product in the equilibrium was believed to be **11**.

Thus, the stepwise addition of isocyanate **10** to the C=C double bond of enamide **11** gave rise to the regiospecific

(14) Fry, A. J. *Am. Chem. Soc.* **1953**, *75*, 2686–2688.

(15) Lenz, G. R. *Synthesis* **1978**, 489–518.

SCHEME 4. Mechanism of Acid-Promoted Cycloaddition of Acryloyl Azide



[2+2] cycloadduct **14** through the zwitterionic intermediate **13** (path a).¹⁶ The reaction proceeded in polar solvents, such as DMSO or DMF, further supporting the existence of the polar **13**. In addition, the [4+2] cycloadduct **18** was also formed with the same intermediate **13**.^{16a} Hydrogen-shift as well as loss of acetyl carbamate **17** afforded pyridinone **9**. The isolation of **9a** supported the formation of the [4+2] adduct. The more stable **13x**, with a negative charge on the nitrogen, compared with **13y**, with a negative charge on carbon, led to [2+2] adduct **14**. Subsequently, cycloreversion of **14** formed 2-aza-1,3-butadiene derivative **15** and acyl ketene. The reaction of **15** and **11** through the polar intermediate **19x** generated a regioselective [4+2] cycloadduct **16**, which was known to occur under acidic conditions.^{9a,17} Finally, tetrahydropyridine **16**, with loss of 2 equiv of **17**, converted into pyridine **5**. The elimination of **17** was ascertained by the isolation of acetamide since it was known that the acetic acid adduct **17** of isocyanic acid ($\text{HN}=\text{C}=\text{O}$) easily loses CO_2 to form acetamide by heating.¹³

An alternative path to the formation of disubstituted pyridine **5** (path b) was proposed through cycloaddition of the isocyanate **10** to the $\text{C}=\text{N}$ double bond of mixed

anhydride **12**.^{16a,18} Both regioselective [2+2] adduct **21** and [4+2] adduct **25** were similarly generated through the polar intermediate **20**. Hydrogen-shift followed by hydrolysis upon basic workup converted **25** into pyrimidinone **8**. Cycloreversion of **21** formed another 2-aza-1,3-butadiene **22** and isocyanate derivative **23**. The elimination product **23** was transformed to diacetamide, which would further decompose to acetamide and ketene.¹⁹ Subsequently, the [4+2] cycloaddition of **22** to the $\text{C}=\text{C}$ double bond of acetic acid adducts **11** gave tetrahydropyridine **24**. The generation of regioselective **24** also probably occurred through zwitterion **19y**. The presence of the intermediate **24** was supported by the fact that 2-butoxymethyl-5-butoxypyridine **7**, not 3,5-dibutoxypyridine **5k** or 2-butoxymethyl-3,5-dibutoxypyridine **6k**, was obtained from the acid-promoted reaction of 3-butoxyacryloyl azide **4k**. This might be the result of the good leaving ability of the butoxy group. Finally, tetrahydropyridine **24** transferred to pyridines **5** and **6** by loss of **17** followed by elimination of RCH_3 ^{7a} or oxidation, respectively. The isolation of 3-nitrotoluene in the case of heating **4f** supported this alternative process to the formation of **5**. Owing to the yield of 3-nitrotoluene being 5%, not comparable with that of **5f** (66%), the former mechanistic path was proposed as the major route.

(16) (a) Ulrich, H. *Acc. Chem. Res.* **1969**, *2*, 186–192. (b) Abdulla, R. F.; Fuhr, K. H. *J. Med. Chem.* **1975**, *18*, 625–627.

(17) Komatsu, M.; Takamatsu, S.; Uesaka, M.; Yamamoto, S.; Ohshiro, Y. *J. Org. Chem.* **1984**, *49*, 2691–2699.

(18) Tisler, M.; Stanovnik, B. *J. Chem. Soc., Chem. Commun.* **1980**, 313–314.

(19) Taylor, R. *J. Chem. Soc., Perkin Trans. 2* **1983**, 89–95.

Conclusion

In summary, a series of pyridine derivatives was synthesized from the corresponding acryloyl azides by the acetic acid-promoted cycloaddition. The reaction involved a trimolecular condensation mechanism. The yield of the pyridine product depends on the substituent on the double bond and the solvent used. The reactivity of the acid-promoted cycloaddition increases with the presence of aryl groups, such as phenyl and pyridinyl. Here, we report a novel and convenient synthetic approach to the symmetrical 3,5-disubstituted pyridines from acryloyl azides.

Experimental Section

General Procedure for the Acid-Promoted Cycloaddition of an Acryloyl Azide, 4. A mixture of acryloyl azide **4** (4 mmol) and HOAc (3.00 g, 40 mmol) in DMSO (4 mL) was heated under N₂ at 150 °C for 4 h. After cooling, the resulting solution was diluted with ethyl acetate (400 mL), washed with 4 N aqueous NaOH (16 mL) and water (8 × 25 mL), dried with anhydrous MgSO₄, and filtered. The filtrate was concentrated, and the residue was purified by column chromatography over Al₂O₃ eluting with hexane–EtOAc (5:1) to give pyridine derivatives **5a–j**, **6a–d**, **6j**, and **7**, as well as the pyrimidinone **8a** and pyridinone **9a** when **4a** was used. The full spectral data of these compounds are described as follows.

3,5-Diphenylpyridine (5a). Yield 62%; white solid, mp 137–138 °C (hexane–EtOAc) (lit.²⁰ mp 137–138 °C); ¹H NMR (300 MHz, CDCl₃) δ 7.43 (2H, t, *J* = 7.5 Hz, 2 × H-4'), 7.51 (4H, t, *J* = 7.5 Hz, 4 × H-3'), 7.65 (4H, d, *J* = 7.5 Hz, 4 × H-2'), 8.05 (1H, t, *J* = 2.2 Hz, H-4), 8.83 (2H, d, *J* = 2.2 Hz, 2 × H-2); ¹³C NMR (75 MHz, CDCl₃) δ 127.3 (4 × C-2'), 128.2 (2 × C-4'), 129.1 (4 × C-3'), 132.9 (C-4), 136.7 (2 × C-3), 137.8 (2 × C-1'), 147.0 (2 × C-2); IR (KBr) 3021, 1598, 1584 cm⁻¹; EIMS *m/z* (rel int) 231 (100, M⁺). Anal. Calcd for C₁₇H₁₃N: C, 88.28; H, 5.67; N, 6.06. Found: C, 88.20; H, 5.67; N, 6.02.

3,5-Diphenyl-[2,4,6-¹³C₃]pyridine (5a-¹³C). Yield 51%; white solid, mp 139–140 °C (hexane–EtOAc); ¹H NMR (300 MHz, CDCl₃) δ 7.47 (6H, m), 7.65 (4H, m), 8.05 (1H, dt, *J* = 159.3, 5.6, 2.2 Hz, H-4), 8.82 (2H, dddd, *J* = 165.4, 10.2, 5.5, 2.2 Hz, 2 × H-2); ¹³C NMR (75 MHz, CDCl₃) two labeled signals δ 132.9 (C-4), 147.0 (2 × C-2); IR (KBr) 3035, 1599, 1578 cm⁻¹; EIMS *m/z* (rel int) 234 (100, M⁺); HREIMS *m/z* calcd for ¹²C₁₄¹³C₃H₁₃N 234.1148, found 234.1145 [M]⁺.

3,5-Bis(4-methoxyphenyl)pyridine (5b). Yield 47%; white solid, mp 233–235 °C (hexane–EtOAc) (lit.²¹ mp 229 °C); ¹H NMR (CDCl₃) δ 3.87 (6H, s), 7.03 (4H, d, *J* = 8.7 Hz), 7.58 (4H, d, *J* = 8.7 Hz), 7.96 (1H, t, *J* = 2.0 Hz), 8.74 (2H, d, *J* = 2.0 Hz); ¹³C NMR (CDCl₃) δ 55.4, 114.6, 128.3, 130.3, 131.9, 136.2, 146.1, 159.8; IR (KBr) 3013, 1609, 1513 cm⁻¹; EIMS *m/z* (rel int) 291 (100, M⁺). Anal. Calcd for C₁₉H₁₇NO₂: C, 78.33; H, 5.88; N, 4.81. Found: C, 78.02; H, 5.80; N, 4.67.

3,5-Bis(3-methoxyphenyl)pyridine (5c). Yield 58%; white solid, mp 110–111 °C (hexane–EtOAc) (lit.^{10e} mp 111 °C); ¹H NMR (300 MHz, CDCl₃) δ 3.86 (6H, s), 6.96 (2H, dd, *J* = 8.0, 2.1 Hz), 7.15 (2H, br s), 7.21 (2H, d, *J* = 8.0 Hz), 7.40 (2H, t, *J* = 8.0 Hz), 8.02 (1H, br s), 8.81 (2H, br s); ¹³C NMR (75 MHz, CDCl₃) δ 55.3, 112.9, 113.4, 119.6, 130.1, 132.8, 136.4, 139.1, 147.0, 160.1; IR (KBr) 3001, 1607, 1584 cm⁻¹; EIMS *m/z* (rel int) 291 (100, M⁺). Anal. Calcd for C₁₉H₁₇NO₂: C, 78.33; H, 5.88; N, 4.81. Found: C, 77.95; H, 5.97; N, 4.80.

3,5-Bis(2-methoxyphenyl)pyridine (5d). Yield 51%; white solid, mp 125–126 °C (hexane–EtOAc); ¹H NMR (300 MHz,

CDCl₃) δ 3.83 (6H, s), 7.04 (4H, m), 7.36 (4H, m), 8.02 (1H, br s), 8.72 (2H, br s); ¹³C NMR (75 MHz, CDCl₃) δ 55.5, 111.2, 121.0, 127.1, 129.4, 130.7, 133.3, 137.6, 148.4, 156.6; IR (KBr) 3003, 1601, 1582 cm⁻¹; EIMS *m/z* (rel int) 291 (100, M⁺). Anal. Calcd for C₁₉H₁₇NO₂: C, 78.33; H, 5.88; N, 4.81. Found: C, 78.30; H, 5.76; N, 4.65.

3,5-Bis(4-nitrophenyl)pyridine (5e). Yield 48%; white solid, mp 315–317 °C (EtOAc) (lit.^{12b} mp 222–224 °C); ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.21 (4H, d, *J* = 8.4 Hz), 8.37 (4H, d, *J* = 8.4 Hz), 8.60 (1H, br s), 9.10 (2H, br s); ¹³C NMR (75 MHz, CDCl₃) δ 124.1, 128.6, 133.5, 133.7, 143.2, 147.4, 148.3; IR (KBr) 3030, 1672, 1601, 1512 cm⁻¹; EIMS *m/z* (rel int) 321 (100, M⁺). Anal. Calcd for C₁₇H₁₁N₃O₄: C, 63.55; H, 3.45; N, 13.08. Found: C, 63.34; H, 3.45; N, 13.23.

3,5-Bis(3-nitrophenyl)pyridine (5f). Yield 66%; white solid, mp 257–259 °C (EtOAc–CH₂Cl₂); ¹H NMR (300 MHz, CDCl₃) δ 7.74 (2H, t, *J* = 8.0 Hz), 8.01 (2H, dt, *J* = 8.0, 1.9 Hz), 8.15 (1H, t, *J* = 2.2 Hz), 8.34 (2H, dt, *J* = 8.0, 1.9 Hz), 8.53 (2H, t, *J* = 1.9 Hz), 8.96 (2H, d, *J* = 2.2 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 122.2, 123.3, 130.4, 133.0, 132.2, 134.7, 138.9, 148.0, 148.9; IR (KBr) 3049, 1521, 1352 cm⁻¹; EIMS *m/z* (rel int) 321 (100, M⁺). Anal. Calcd for C₁₇H₁₁N₃O₄: C, 63.55; H, 3.45; N, 13.08. Found: C, 63.40; H, 3.39; N, 12.92.

3,5-Bis(2-nitrophenyl)pyridine (5g). Yield 58%; white solid, mp 141–142 °C (hexane–EtOAc); ¹H NMR (300 MHz, CDCl₃) δ 7.50 (2H, d, *J* = 7.4 Hz), 7.59 (3H, m), 7.72 (2H, t, *J* = 7.4 Hz), 8.03 (2H, d, *J* = 8.2 Hz), 8.62 (2H, br s); ¹³C NMR (75 MHz, CDCl₃) δ 124.8, 129.4, 132.4, 132.5, 133.0, 133.3, 135.0, 148.0, 148.7; IR (KBr) 3032, 1530, 1348 cm⁻¹; EIMS *m/z* (rel int) 321 (100, M⁺). Anal. Calcd for C₁₇H₁₁N₃O₄: C, 63.55; H, 3.45; N, 13.08. Found: C, 63.41; H, 3.27; N, 12.77.

3,5-Bis(pyridine-3-yl)pyridine (5h). Yield 70%; white solid, mp 157–158 °C (hexane–EtOAc) (lit.²² mp 159–160 °C); ¹H NMR (300 MHz, CDCl₃) δ 7.47 (2H, dd, *J* = 8.0, 4.8 Hz), 7.96 (2H, m), 8.06 (1H, t, *J* = 2.0 Hz), 8.71 (2H, m), 8.91 (4H, m); ¹³C NMR (75 MHz, CDCl₃) δ 123.9, 132.9, 133.1, 133.8, 134.6, 147.7, 148.3, 149.7; IR (KBr) 3026, 1568, 1481, 1447, 1400 cm⁻¹; EIMS *m/z* (rel int) 233 (100, M⁺). Anal. Calcd for C₁₅H₁₁N₃: C, 77.23; H, 4.75; N, 18.01. Found: C, 77.03; H, 4.65; N, 17.71.

3,5-Bis(ethoxycarbonyl)pyridine (5i). Yield 33%; white solid, mp 48–48.5 °C (hexane) (lit.²³ mp 48.5–50 °C); ¹H NMR (300 MHz, CDCl₃) δ 1.44 (6H, t, *J* = 7.1 Hz), 4.46 (4H, q, *J* = 7.1 Hz), 8.86 (1H, t, *J* = 1.9 Hz), 9.37 (2H, d, *J* = 1.9 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 14.2, 61.8, 126.3, 137.9, 154.1, 164.5; IR (KBr) 2988, 1717, 1605 cm⁻¹; EIMS *m/z* (rel int) 223 (100, M⁺); HREIMS *m/z* calcd for C₁₁H₁₃NO₄ 223.0845, found 223.0842 [M]⁺.

3,5-Dipropylpyridine (5j). Yield 2%; colorless liquid; ¹H NMR (300 MHz, CDCl₃) δ 0.95 (6H, t, *J* = 7.4 Hz), 1.64 (4H, sextet, *J* = 7.4 Hz), 2.56 (4H, t, *J* = 7.4 Hz), 7.29 (1H, t, *J* = 1.9 Hz), 8.26 (2H, d, *J* = 1.9 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 13.7, 24.3, 34.9, 135.9, 137.2, 147.4; IR (KBr) 2961, 1456 cm⁻¹; EIMS *m/z* (rel int) 163 (43, M⁺); HREIMS *m/z* calcd for C₁₁H₁₇N 163.1361, found 163.1365 [M]⁺.

2-Benzyl-3,5-diphenylpyridine (6a). Yield 12%; white solid, mp 72–73 °C (hexane–EtOAc) (lit.²⁴ mp 74–75 °C); ¹H NMR (300 MHz, CDCl₃) δ 4.19 (2H, s, CH₂), 7.05 (2H, d, *J* = 7.4 Hz, 2 × H-2''), 7.14 (1H, t, *J* = 7.4 Hz, H-4'''), 7.20 (2H, t, *J* = 7.4 Hz, 2 × H-3'''), 7.28 (2H, d, *J* = 7.4 Hz, 2 × H-2'), 7.40 (4H, m, 2 × H-3' and H-4', H-4''), 7.46 (2H, t, *J* = 7.4 Hz, 2 × H-3''), 7.61 (2H, d, *J* = 7.4 Hz, 2 × H-2''), 7.75 (1H, d, *J* = 2.0 Hz, H-4), 8.83 (1H, d, *J* = 2.0 Hz, H-6); ¹³C NMR (75 MHz, CDCl₃) δ 41.3 (CH₂), 126.0 (C-4'''), 127.0 (2 × C-2''), 127.7 (C-4'), 128.0

(20) Gopinath, K. W.; Govindachari, T. R.; Nagarajan, K.; Purushothaman, K. *J. Chem. Soc.* **1957**, 1144–1148.

(21) Brown, D. J.; England, B. T. *Aust. J. Chem.* **1970**, *23*, 625–627.

(22) Ishikura, M.; Ohta, T.; Terashima, M. *Chem. Pharm. Bull.* **1985**, *33*, 4755–4763.

(23) Dieterich, D. *Synthesis* **1972**, 631–632.

(24) Folkers, K.; Johnson, J. B. *J. Am. Chem. Soc.* **1933**, *55*, 3361–3368.

(C-4''), 128.2 (2 × C-3'''), 128.4 (2 × C-3'), 128.8 (2 × C-2'''), 129.1 (2 × C-3''), 129.2 (2 × C-2'), 134.2 (C-5), 136.1 (C-4), 137.3 (C-3), 137.5 (C-1''), 139.6 (C-1'), 140.0 (C-1'''), 146.7 (C-6), 156.6 (C-2); IR (KBr) 3028, 1601 cm⁻¹; FABMS *m/z* (rel int) 322 (100, [MH]⁺); HRFABMS *m/z* calcd for C₂₄H₂₀N 322.1592, found 322.1602 [MH]⁺.

2-Benzyl-3,5-diphenyl-[2,4,6-¹³C₃]pyridine (6a-¹³C). Yield 4%; white solid, mp 72–73 °C (hexane–EtOAc); ¹H NMR (400 MHz, CDCl₃) δ 4.19 (2H, d, *J* = 6.5 Hz, CH₂), 7.05 (2H, d, *J* = 7.0 Hz), 7.14 (1H, t, *J* = 7.0 Hz), 7.20 (2H, t, *J* = 7.0 Hz), 7.27 (2H, dd, *J* = 7.5, 2.0 Hz), 7.40 (4H, m), 7.46 (2H, t, *J* = 7.5 Hz), 7.61 (2H, dd, *J* = 7.5, 2.0 Hz), 7.74 (1H, dtd, *J* = 159.7, 6.1, 2.4 Hz, H-4), 8.83 (1H, dddd, *J* = 177.6, 11.2, 5.5, 2.4 Hz, H-6); ¹³C NMR (100 MHz, CDCl₃) three labeled signals δ 136.1 (C-4), 146.7 (C-6), 156.6 (C-2); IR (KBr) 3028, 1601 cm⁻¹; EIMS *m/z* (rel int) 324 (35, M⁺); HREIMS *m/z* calcd for ¹²C₂₁¹³C₃H₁₉N 324.1618, found 324.1610 [M]⁺.

2-(4-Methoxybenzyl)-3,5-Bis(4-methoxyphenyl)pyridine (6b). Yield 6%; syrup; ¹H NMR (300 MHz, CDCl₃) δ 3.75 (3H, s), 3.85 (3H, s), 3.87 (3H, s), 4.11 (2H, s), 6.76 (2H, d, *J* = 8.6 Hz), 6.97 (6H, m), 7.20 (2H, d, *J* = 8.6 Hz), 7.53 (2H, d, *J* = 8.6 Hz), 7.67 (1H, d, *J* = 2.3 Hz), 8.76 (1H, d, *J* = 2.3 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 40.3, 55.2, 55.3 (2 × C), 113.7, 113.8, 114.5, 128.1, 129.7, 130.0, 130.4, 132.1, 132.3, 133.7, 135.8, 136.8, 146.1, 156.5, 157.8, 159.1, 159.6; IR (KBr) 2933, 1611, 1512 cm⁻¹; EIMS *m/z* (rel int) 411 (72, M⁺); HREIMS *m/z* calcd for C₂₇H₂₅NO₃ 411.1834, found 411.1829 [M]⁺.

2-(3-Methoxybenzyl)-3,5-bis(3-methoxyphenyl)pyridine (6c). Yield 7%; syrup; ¹H NMR (300 MHz, CDCl₃) δ 3.72 (3H, s), 3.73 (3H, s), 3.85 (3H, s), 4.17 (2H, s), 6.67 (3H, m), 6.78 (1H, t, *J* = 1.9 Hz), 6.91 (3H, m), 7.15 (3H, m), 7.36 (2H, m), 7.74 (1H, d, *J* = 2.3 Hz), 8.83 (1H, d, *J* = 2.3 Hz); ¹³C NMR (400 MHz, CDCl₃) δ 41.3, 55.0, 55.1, 55.3, 111.5, 112.6, 113.4, 113.5, 114.4, 114.6, 119.4, 121.2, 121.5, 129.1, 129.4, 130.1, 134.1, 136.0, 137.2, 138.9, 140.8, 141.6, 146.7, 156.5, 159.4, 159.5, 160.1; IR (KBr) 2938, 1602, 1584 cm⁻¹; FABMS *m/z* (rel int) 412 (100, [MH]⁺); HRFABMS *m/z* calcd for C₂₇H₂₆NO₃ 412.1913, found 412.1920 [MH]⁺.

2-(2-Methoxybenzyl)-3,5-bis(2-methoxyphenyl)pyridine (6d). Yield 10%; syrup; ¹H NMR (300 MHz, CDCl₃) δ 3.60 (3H, s), 3.65 (3H, s), 3.77 (3H, s), 4.07 (2H, s), 6.70 (1H, d, *J* = 8.2 Hz), 6.80 (1H, t, *J* = 7.7 Hz), 7.00 (7H, m), 7.33 (3H, m), 7.71 (1H, d, *J* = 2.2 Hz), 8.76 (1H, d, *J* = 2.2 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 35.0, 55.1 (2 × C), 55.4, 109.9, 110.5, 111.1, 120.1, 120.2, 120.9, 126.8, 126.9, 128.7 (2 × C), 128.9, 129.1, 130.2, 130.6, 131.1 (2 × C), 133.3, 138.8, 148.5, 156.6 (2 × C), 157.0, 157.3; IR (KBr) 2936, 1601, 1584 cm⁻¹; EIMS *m/z* (rel int) 411 (25, M⁺); HREIMS *m/z* calcd for C₂₇H₂₅NO₃ 411.1834, found 411.1838 [M]⁺.

2-Butyl-3,5-dipropylpyridine (6j). Yield 21%; colorless liquid; ¹H NMR (300 MHz, CDCl₃) δ 0.96 (9H, m), 1.42 (2H, sextet,

J = 7.4 Hz), 1.63 (6H, m), 2.52 (2H, t, *J* = 7.8 Hz), 2.56 (2H, t, *J* = 7.5 Hz), 2.75 (2H, t, *J* = 7.8 Hz), 7.21 (1H, s), 8.20 (1H, s); ¹³C NMR (75 MHz, CDCl₃) δ 13.7, 14.0 (2 × C), 23.0, 23.9, 24.3, 32.0, 34.2, 34.3, 34.6, 134.5, 134.7, 136.8, 146.6, 157.6; IR (KBr) 2959, 1460 cm⁻¹; EIMS *m/z* (rel int) 219 (8, M⁺); HREIMS *m/z* calcd for C₁₅H₂₅N 219.1987, found 219.1981 [M]⁺.

2-Butoxymethyl-5-butoxypyridine (7). Yield 10%; colorless liquid; ¹H NMR (300 MHz, CDCl₃) δ 0.92 (3H, t, *J* = 7.4 Hz), 0.98 (3H, t, *J* = 7.4 Hz), 1.46 (4H, m), 1.63 (2H, m), 1.78 (2H, m), 3.53 (2H, t, *J* = 6.6 Hz), 4.00 (2H, t, *J* = 6.5 Hz), 4.56 (2H, s), 7.19 (1H, dd, *J* = 8.6, 2.8 Hz), 7.34 (1H, d, *J* = 8.6 Hz), 8.23 (1H, d, *J* = 2.8 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 13.7, 13.9, 19.1, 19.3, 31.1, 31.8, 68.1, 70.6, 73.4, 121.7, 122.0, 136.9, 150.5, 154.3; IR (KBr) 2961, 1248, 1119 cm⁻¹; FABMS *m/z* (rel int) 238 (100, [MH]⁺); HRFABMS *m/z* calcd for C₁₄H₂₄NO₂ 238.1807, found 238.1808 [MH]⁺.

4-Benzyl-5-phenyl-3,4-dihydro-1H-pyrimidin-2-one (8a). White solid; mp 215–217 °C (hexane–acetone) (lit.²⁴ mp 212–214 °C); ¹H NMR (300 MHz, CDCl₃) δ 2.77 (1H, dd, *J* = 13.5, 9.0 Hz), 2.94 (1H, dd, *J* = 13.5, 2.7 Hz), 4.69 (1H, m), 5.26 (1H, br s), 6.44 (1H, d, *J* = 5.1 Hz), 7.29 (10H, m), 7.47 (1H, br s); ¹³C NMR (75 MHz, CDCl₃) δ 42.2, 55.3, 113.7, 121.7, 124.7, 126.8, 128.7, 129.0, 129.6, 135.9, 136.7, 154.1; IR (KBr) 3225, 1713, 1669 cm⁻¹; EIMS *m/z* (rel int) 264 (20, M⁺). Anal. Calcd for C₁₇H₁₆N₂O: C, 77.25; H, 6.10; N, 10.60. Found: C, 77.12; H, 6.12; N, 10.53.

3,5-Diphenylpyridin-2-one (9a). White solid; mp 206–207 °C (hexane–EtOAc) (lit.²⁵ mp 202 °C); ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.29 (1H, t, *J* = 7.5 Hz), 7.33 (1H, t, *J* = 7.3 Hz), 7.40 (4H, m), 7.64 (2H, d, *J* = 7.5 Hz), 7.70 (1H, d, *J* = 2.6 Hz), 7.81 (2H, d, *J* = 7.3 Hz), 7.95 (1H, d, *J* = 2.6 Hz), 12.02 (1H, br s); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 118.5, 125.7, 126.9, 127.6, 128.0, 128.6, 129.1, 130.2, 131.9, 136.4, 136.8, 137.8, 160.8; IR (KBr) 3421, 1633, 1567, 1514 cm⁻¹; EIMS *m/z* (rel int) 247 (100, M⁺); HREIMS *m/z* calcd for C₁₇H₁₃NO 247.0997, found 247.1004 [M]⁺.

Acknowledgment. Financial support from the National Science Council of the Republic of China (NSC 97-2113-M-039-004-MY2) and China Medical University (CMU97-285 and CMU98-NMR) are gratefully acknowledged.

Supporting Information Available: The synthetic procedures, spectroscopic data of **3a-¹³C** and acryloyl azides **4**, and copies of ¹H and ¹³C NMR spectra of all compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

(25) Hirai, K.; Matsuda, H.; Kishida, Y. *Chem. Pharm. Bull.* **1973**, *21*, 1090–1095.